These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 7034276)

  • 1. Clinical management of beta-thalassemia.
    Graziano J; Piomelli S
    Tex Rep Biol Med; 1980-1981; 40():355-64. PubMed ID: 7034276
    [No Abstract]   [Full Text] [Related]  

  • 2. Reduction of iron overload in thalassemia.
    Piomelli S; Graziano J
    Birth Defects Orig Artic Ser; 1982; 18(7):339-46. PubMed ID: 7159742
    [No Abstract]   [Full Text] [Related]  

  • 3. Medical management of beta-thalassemia.
    Lerner N
    Prog Clin Biol Res; 1989; 309():13-22. PubMed ID: 2780747
    [No Abstract]   [Full Text] [Related]  

  • 4. Cardiac complications in homozygous beta-thalassemia.
    Wonke B; Hoffbrand AV; Aldouri MA; Ward SE
    Prog Clin Biol Res; 1989; 309():51-6. PubMed ID: 2780750
    [No Abstract]   [Full Text] [Related]  

  • 5. Advances in the use of iron-chelating agents for the treatment of iron overload.
    Modell B
    Prog Hematol; 1979; 11():267-312. PubMed ID: 392593
    [No Abstract]   [Full Text] [Related]  

  • 6. [Chelating therapy in beta-thalassemia].
    Musumeci S; Romeo MA; Di Gregorio F; Schiliró G; Russo G
    Pediatr Med Chir; 1982; 4(1-2):55-9. PubMed ID: 7111040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Our experience with "supertransfusive" treatment of homozygous beta-thalassemia].
    Esposito L; Ferrara M; Ponte G
    Pediatria (Napoli); 1983; 91(1):27-30. PubMed ID: 6889088
    [No Abstract]   [Full Text] [Related]  

  • 8. Desferrioxamine-induced iron outputs in Cooley's anemia. Results and perspectives.
    Cantore N; Tortarolo M; Volpe E; Gonnella F; Valente A; Buonanno G
    Haematologica; 1981 Apr; 66(2):196-207. PubMed ID: 6791996
    [No Abstract]   [Full Text] [Related]  

  • 9. The management of the improved prognosis in thalassemia major.
    Modell B
    Birth Defects Orig Artic Ser; 1982; 18(7):329-37. PubMed ID: 6819016
    [No Abstract]   [Full Text] [Related]  

  • 10. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
    Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensive iron chelation therapy in beta-thalassemia major: some effects on iron metabolism and blood transfusion dependence.
    Silvestroni E; Bianco I; Graziani B; Lerone M; Valente M; Congedo P; Ponzini D; Costantini S
    Acta Haematol; 1982; 68(2):115-23. PubMed ID: 6812366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose intravenous chelation therapy with deferoxamine.
    Cohen A; Mizanin J; Schwartz E
    Prog Clin Biol Res; 1989; 309():125-31. PubMed ID: 2780746
    [No Abstract]   [Full Text] [Related]  

  • 13. Oral ascorbic acid and iron excretion in thalassemic children treated with desferrioxamine-methansulfonate (Desferal).
    Hathirat P; Isarangkura P; Areekul S; Pleehachinda R; Tuntawiroon M
    Birth Defects Orig Artic Ser; 1988; 23(5B):129-33. PubMed ID: 3390535
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term effect of splenectomy on transfusion requirements in thalassemia major.
    Cohen A; Gayer R; Mizanin J
    Am J Hematol; 1989 Apr; 30(4):254-6. PubMed ID: 2929586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of life and life expectancy in thalassemic patients with complications.
    Gabutti V; Piga A; Sacchetti L; Sandri A; Biginelli M; Saracco P; Ferri M
    Prog Clin Biol Res; 1989; 309():35-41. PubMed ID: 2780748
    [No Abstract]   [Full Text] [Related]  

  • 16. Infections and Cooley disease.
    Schiliro G; Romeo MA; Di Gregorio F; Sciacca A; Musumeci S; Russo G
    Birth Defects Orig Artic Ser; 1987; 23(5A):487-93. PubMed ID: 3318951
    [No Abstract]   [Full Text] [Related]  

  • 17. Compliance with therapy in Cooley's anaemia.
    Vullo C; Di Palma A
    Prog Clin Biol Res; 1989; 309():43-9. PubMed ID: 2780749
    [No Abstract]   [Full Text] [Related]  

  • 18. [Serum ferritin in the follow-up of homozygotic beta-thalassemia treated with blood transfusion and iron-chelating agents].
    Esposito L; Ferrara M; Ponte G
    Pediatria (Napoli); 1981 Sep; 89(3):479-92. PubMed ID: 7346759
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of iron overload in Cooley's anemia.
    Cohen A; Mizanin J; Schwartz E
    Ann N Y Acad Sci; 1985; 445():274-81. PubMed ID: 3860130
    [No Abstract]   [Full Text] [Related]  

  • 20. Chelation therapy, transfusion requirement, and iron balance in young thalassemic patients.
    Piomelli S; Graziano J; Karpatkin M; Dudell GG; Hart D; Hilgartner M; Khanna K; Valdes-Cruz LM; Vora S
    Ann N Y Acad Sci; 1980; 344():409-17. PubMed ID: 6930881
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.